United States : U.S. FDA Approves New DARZALEX (daratumumab)-Based Combination Regimen for Patients with Relapsed|Refractory Multiple Myeloma

Source :: Mena Report. August 21, 2020
Publication Year :: 2020
Abstract: The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) approval of DARZALEX (daratumumab) in combination with Kyprolis (carfilzomib) and dexamethasone (DKd) for the [...]

Subjects :: United States. Food and Drug Administration
Johnson & Johnson
Carfilzomib
Recurrence (Disease) -- Drug therapy
Multiple myeloma -- Drug therapy
Daratumumab
Drug approval
Pharmaceutical industry
Business, international
Darzalex (Medication)

Tools